Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DarPharma
DAR-0100 to be evaluated in trial for working memory deficits in schizophrenia
September 24th, 2004
DarPharma announced that enrollment has begun for a trial of DAR-0100 for the treatment of working memory and cognitive deficits associated with schizophrenia. This is the first-ever clinical trial of a dopamine D1 receptor full agonist in treating working memory deficits. The trial is sponsored by The Stanley Medical Research Institute (SMRI), the largest private source of funding for research into schizophrenia and bipolar disease. "SMRI is dedicated to finding ways to improve the quality of life of people with schizophrenia and bipolar disorder," said Dr. Michael Knable, executive director of SMRI and a member of DarPharma's board of directors....
Source: Food & Drug Law Weekly (2004-09-24)
|
